As we reflect on the year, we’re especially grateful for the incredible dedication and passion of our team at Elixirgen Therapeutics, our advisors, and the community that supports us. Together, we have the potential to make a lasting difference for patients.
Elixirgen Therapeutics, Inc.
Biotechnology
BALTIMORE, Maryland 1,073 followers
Reimagine the Power of RNA
About us
Elixirgen Therapeutics is a clinical-stage RNA therapeutics company focused on the discovery and development of innovative therapies, including cell and gene therapies. The Company is advancing three technologies to develop therapeutics for a broad spectrum of diseases including rare and genetic diseases, and aging-related disorders. Bobcat mRNA™ technology uses a proprietary mRNA design to deliver large payloads such as full-length dystrophin, which is mutated in Duchenne muscular dystrophy. Preclinical data have demonstrated restoration of muscular function in DMD model mice with no safety findings associated with administration or treatment. Controllable self-replicating (c-srRNA™) technology controls the powerful gene expression of self-replicating RNA to reduce off-target effects and improve efficacy. ZSCAN4 technology, delivered via the RNA-based Sendai virus, is currently in a Phase 1/2 clinical trial to extend telomeres in patients with telomere biology disorders (TBDs), a rare disease with significant unmet need. Initial data have demonstrated ex vivo telomere elongation in TBD patients for the first time ever and suggest the potential emergence of a cell population with longer telomeres in vivo. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore.
- Website
-
https://ElixirgenTx.com/
External link for Elixirgen Therapeutics, Inc.
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- BALTIMORE, Maryland
- Type
- Privately Held
- Founded
- 2017
- Specialties
- Therapeutics, Drug Development, and Biotechnology
Locations
-
Primary
Get directions
BALTIMORE, Maryland 21205, US
Employees at Elixirgen Therapeutics, Inc.
Updates
-
In case you missed it, this Bioprocess Online article highlights how we're pioneering a decentralized approach to manufacturing and delivery, offering potential logistical and efficacy benefits in #CellTherapy. Read the article here: https://lnkd.in/g5-4Sbhn
-
🧬 November is #TBDMonth! We're developing a therapy to treat #TelomereBiologyDisorders, a #RareDisease characterized by shortened #telomeres. Join us in raising awareness & supporting innovative solutions for those affected. Learn more from Team Telomere here: https://bit.ly/40oUc9d
-
-
Did you know that while #DuchenneMuscularDystrophy is a rare muscle disorder, it is one of the most frequent genetic conditions, affecting 1 in 3,500 male births worldwide? At Elixirgen Therapeutics, we're exploring the potential of our Bobcat mRNA™ in treatment for #DMD. Learn more here: https://bit.ly/4euOyXI
-
-
#RNA plays a crucial role in biology and is a powerful tool in modern medicine. At Elixirgen Therapeutics, we are reimagining the power of RNA to develop various technologies for the treatment of #RareDiseases. Learn more here: https://bit.ly/3MZIFVK
-
-
Living with a #TelomereBiologyDisorder can deeply impact patients and their families. As we work to develop a #CellTherapy for TBDs, we are proud to partner with Team Telomere, an organization that is fostering a strong patient community. Read some of the inspiring patient stories here: https://bit.ly/3XAIPYB
-
-
We are pleased to announce that the FDA has granted Rare Pediatric Disease Designation to our candidate for the treatment of #DyskeratosisCongenita and related #TelomereBiologyDisorders. We look forward to working with the FDA as we continue the advancement of our program to address the unmet need in the TBD space. Read the full press release here: https://bit.ly/3XVi9mF
-
-
As we wrap up Muscular Dystrophy Awareness Month (MDAM), we reaffirm our commitment to combatting #DuchenneMuscularDystrophy (DMD) with our Bobcat mRNA™ to restore muscle function. Learn more: https://bit.ly/4euOyXI
-
-
We're attending the Arena International Events Group 2024 Clinical Trials in Rare Diseases Conference! At Elixirgen Therapeutics, we’re committed to developing treatments for rare diseases and to improving the quality of life for patients affected by these conditions. Learn more: https://bit.ly/4cGAEzx
-
-
We're excited to attend two conferences this September: 🧬 RNA Leaders USA Congress 🧬 Arena International Events Group Clinical Trials in Rare Disease Hear from our Co-founder and CEO, @Aki Ko, about our development of cutting-edge #RNA technologies and #CellTherapy. Learn more: https://bit.ly/4euOyXI
-